

DAFTAR PUSTAKA

- Adhyam, M., Gupta, A.K., 2012. A Review on the Clinical Utility of PSA in Cancer Prostate. *Indian J Surg Oncol* 3, 120–129. <https://doi.org/10.1007/s13193-012-0142-6>
- Ahmad M. Saleh, Marjaneh M. Fooladi, Wasileh Petro-Nustas, Ghadeer Dweik, Mohammad H. Abuadas, 2016. Early Detection and Screening For Prostate Cancer 5.
- Bluemn, E., Nelson, P.S., 2012. The androgen/androgen receptor axis in prostate cancer. *Curr Opin Oncol* 24, 251–257. <https://doi.org/10.1097/CCO.0b013e32835105b3>
- Borley, N., Feneley, M.R., 2009. Prostate cancer: diagnosis and staging. *Asian J Androl* 11, 74–80. <https://doi.org/10.1038/aja.2008.19>
- Castro, E., Eeles, R., 2012. The role of BRCA1 and BRCA2 in prostate cancer. *Asian J Androl* 14, 409–414. <https://doi.org/10.1038/aja.2011.150>
- Chen, N., Zhou, Q., 2016. The evolving Gleason grading system. *Chin J Cancer Res* 28, 58–64. <https://doi.org/10.3978/j.issn.1000-9604.2016.02.04>
- Chopra, S., Foltz, W.D., Milosevic, M.F., Toi, A., Bristow, R.G., Ménard, C., Haider, M.A., 2009. Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: a pilot study in men with prostate cancer. *Int J Radiat Biol* 85, 805–813. <https://doi.org/10.1080/09553000903043059>
- Ferry Safriadi, Rainy Umbas, Danarto, Lukman Hakim, Syah Mirsa Warli, Agus Rizal Hamid, Syamsu Hudaya, Jufriady Ismy, Indrawarman Soerohardjo, Suharto Widjanarko, Wayan Yudiana, Eldien Muhammad Shidqy, 2022. Panduan Penanganan Kanker Prostat. Ikatan Ahli Urologi Indonesia.
- Fleshner, K., Carlsson, S.V., Roobol, M.J., 2017. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. *Nat Rev Urol* 14, 26–37. <https://doi.org/10.1038/nrurol.2016.251>
- Hajian-Tilaki, K., 2014. Sample size estimation in diagnostic test studies of biomedical informatics. *Journal of Biomedical Informatics* 48, 193–204. <https://doi.org/10.1016/j.jbi.2014.02.013>

- Harris, W.P., Mostaghel, E.A., Nelson, P.S., Montgomery, B., 2009. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. *Nat Clin Pract Urol* 6, 76–85. <https://doi.org/10.1038/ncpuro1296>
- Hershman, D.L., Unger, J.M., Wright, J.D., Ramsey, S., Till, C., Tangen, C.M., Barlow, W.E., Blanke, C., Thompson, I.M., Hussain, M., 2016. Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Metastatic Prostate Cancer Patients. *JAMA Oncol* 2, 453–461. <https://doi.org/10.1001/jamaoncol.2015.4655>
- Jiang, Y., Meyers, T.J., Emeka, A.A., Cooley, L.F., Cooper, P.R., Lancki, N., Helenowski, I., Kachuri, L., Lin, D.W., Stanford, J.L., Newcomb, L.F., Kolb, S., Finelli, A., Fleshner, N.E., Komisarenko, M., Eastham, J.A., Ehdaie, B., Benfante, N., Logothetis, C.J., Gregg, J.R., Perez, C.A., Garza, S., Kim, J., Marks, L.S., Delfin, M., Barsa, D., Vesprini, D., Klotz, L.H., Loblaw, A., Mamedov, A., Goldenberg, S.L., Higano, C.S., Spillane, M., Wu, E., Carter, H.B., Pavlovich, C.P., Mamawala, M., Landis, T., Carroll, P.R., Chan, J.M., Cooperberg, M.R., Cowan, J.E., Morgan, T.M., Siddiqui, J., Martin, R., Klein, E.A., Brittain, K., Gotwald, P., Barocas, D.A., Dallmer, J.R., Gordetsky, J.B., Steele, P., Kundu, S.D., Stockdale, J., Roobol, M.J., Venderbos, L.D.F., Sanda, M.G., Arnold, R., Patil, D., Evans, C.P., Dall’Era, M.A., Vij, A., Costello, A.J., Chow, K., Corcoran, N.M., Rais-Bahrami, S., Phares, C., Scherr, D.S., Flynn, T., Karnes, R.J., Koch, M., Dhondt, C.R., Nelson, J.B., McBride, D., Cookson, M.S., Stratton, K.L., Farriester, S., Hemken, E., Stadler, W.M., Pera, T., Banionyte, D., Bianco, F.J., Lopez, I.H., Loeb, S., Taneja, S.S., Byrne, N., Amling, C.L., Martinez, A., Boileau, L., Gaylis, F.D., Petkewicz, J., Kirwen, N., Helfand, B.T., Xu, J., Scholtens, D.M., Catalona, W.J., Witte, J.S., 2021. Genetic factors associated with prostate cancer conversion from active surveillance to treatment. *HGG Adv* 3, 100070. <https://doi.org/10.1016/j.xhgg.2021.100070>
- Kishan, A.U., Wang, X., Seiferheld, W., Collette, L., Sandler, K.A., Sandler, H.M., Bolla, M., Maingon, P., De Reijke, T., Hanks, G.E., Nickols, N.G., Rettig, M., Drakaki, A., Reiter, R.E., Spratt, D.E., Kupelian, P.A., Steinberg, M.L., King, C.R., 2019. Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes. *JAMA Oncol* 5, 91–96. <https://doi.org/10.1001/jamaoncol.2018.3732>
- Kumari, S., Sharma, V., Tiwari, R., Maurya, J.P., Subudhi, B.B., Senapati, D., 2022. Therapeutic potential of p53 reactivation in prostate cancer:

Strategies and opportunities. *European Journal of Pharmacology* 919, 174807. <https://doi.org/10.1016/j.ejphar.2022.174807>

Leslie, S.W., Soon-Sutton, T.L., R I, A., Sajjad, H., Skelton, W.P., 2023. Prostate Cancer, in: *StatPearls*. StatPearls Publishing, Treasure Island (FL).

Munjal, A., Leslie, S.W., 2024. Gleason Score, in: *StatPearls*. StatPearls Publishing, Treasure Island (FL).

Narayan, V., Ross, A.E., Parikh, R.B., Nohria, A., Morgans, A.K., 2021. How to Treat Prostate Cancer With Androgen Deprivation and Minimize Cardiovascular Risk. *JACC CardioOncol* 3, 737–741. <https://doi.org/10.1016/j.jaccao.2021.09.014>

Ng, K.L., 2021. The Etiology of Prostate Cancer, in: Bott, S.R., Ng, K.L. (Eds.), *Prostate Cancer*. Exon Publications, Brisbane (AU).

Nungki Septi wulansari, Mieke Marindawati, 2020. Profil Prostate Spesific Antigen (PSA) pada Penyakit Prostat di Rumah Sakit Umum Daerah Cengkareng Jakarta Barat 1.

Öztürk, A., Ergin, İ.E., Asdemir, A., Saygın, H., 2024. Predicting Response to Androgen Deprivation Therapy and Resistance to Castration in Metastatic Prostate Cancer. *Grand J Urol* 4, 83–88. <https://doi.org/10.5505/GJU.2024.54227>

Prostate-Specific Antigen (PSA) Test - NCI [WWW Document], 2024. URL <https://www.cancer.gov/types/prostate/psa-fact-sheet> (accessed 1.24.25).

Roberts, M.J., Teloken, P., Chambers, S.K., Williams, S.G., Yaxley, J., Samaratunga, H., Frydenberg, M., Gardiner, R.A. ('Frank'), 2018. Table 8, TNM Staging Classifications [per American Joint Committee on Cancer (AJCC) 8th Edition 2016](198) [WWW Document]. URL <https://www.ncbi.nlm.nih.gov/books/NBK279042/table/prostate-cancer-det.primarytum/> (accessed 2.21.25).

Sekhoacha, M., Riet, K., Motloug, P., Gumenku, L., Adegoke, A., Mashele, S., 2022. Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches. *Molecules* 27, 5730. <https://doi.org/10.3390/molecules27175730>

Suzuki, K., Kise, H., Nishioka, J., Hayashi, T., 2007. The interaction among

protein C inhibitor, prostate-specific antigen, and the semenogelin system. *Semin Thromb Hemost* 33, 46–52. <https://doi.org/10.1055/s-2006-958461>

The Global Cancer Observatory, 2021. Indonesia.

Yang, D.D., Chen, M.-H., Wu, J., Braccioforte, M.H., Moran, B.J., D'Amico, A.V., 2022. The risk of death from prostate cancer in men with Gleason score 3+4 prostate cancer treated using brachytherapy with or without a short course of androgen deprivation therapy. *Urologic Oncology: Seminars and Original Investigations* 40, 6.e21-6.e27. <https://doi.org/10.1016/j.urolonc.2021.06.022>

Yang, D.D., Mahal, B.A., Muralidhar, V., Martin, N.E., Orio, P.F., Mouw, K.W., King, M.T., Choueiri, T.K., Trinh, Q.-D., Hoffman, K.E., Spratt, D.E., Feng, F.Y., Nguyen, P.L., 2019. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9–10 Prostate Cancer. *European Urology* 75, 35–41. <https://doi.org/10.1016/j.eururo.2018.08.033>

Yun, J.W., Lee, S., Ryu, D., Park, S., Park, W.-Y., Joung, J.-G., Jeong, J., 2018. Biomarkers Associated with Tumor Heterogeneity in Prostate Cancer. *Transl Oncol* 12, 43–48. <https://doi.org/10.1016/j.tranon.2018.09.003>